Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 2Wilms Tumor 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Neoplasm, Residual 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Carcinogenesis 1

Interventions

pembrolizumab 3fludarabine 3Cyclophosphamide 3Ipilimumab 2smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1sargramostim 1reolysin 1poly ICLC 1peginterferon alfa-2a 1osimertinib 1gusacitinib 1fludarabine phosphate 1eprenetapopt 1epacadostat 1dabrafenib 1cobimetinib 1cemiplimab 1Vorinostat 1Temozolomide 1Radiotherapy 1Radiation 1Poly I-C 1Nivolumab 1Monatide (IMS 3015) 1Methods 1MAPRE1 protein, human 1Interleukin-2 1Interleukin-15 1Interleukin-12 1IT-101 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Skin Neoplasms × Monatide (IMS 3015) × Clear all
NCT01079741 2018-02-13

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
34 enrolled 10 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms, Carcinogenesis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡